公开(公告)号：US20250049804A1

公开(公告)日：2025-02-13

申请号：US18928757

申请日：2024-10-28

Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION ,  Gachon University of Industry-Academic Cooperation

Inventor： Timothy W. CORSON ,  Kamakshi SISHTLA ,  Seung-Yong SEO ,  Bit LEE

IPC: A61K31/519 ,  A61K31/122 ,  A61K31/155 ,  A61K31/343 ,  A61K31/37 ,  A61K31/4025 ,  A61K31/409 ,  A61K31/4196 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/49 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K41/00 ,  A61K45/06 ,  A61P27/02 ,  C07D249/14 ,  C07D487/04 ,  C07K16/22 ,  C12N15/113

Abstract: The invention relates to a method of treatment of a patient with a ferrochelatase inhibitor, or a pharmaceutically acceptable salt thereof, or a derivative thereof. Also, the invention relates to a method of treatment of a patient with a ferrochelatase inhibitor that is a triazolopyrimidinone, or a derivative thereof, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US12220405B2

公开(公告)日：2025-02-11

申请号：US17342298

申请日：2021-06-08

Applicant: Thomas Winston

Inventor： Thomas Winston

IPC: A61K31/436 ,  A61K31/155 ,  A61K31/232 ,  A61K31/353 ,  A61K38/22 ,  A61K45/06 ,  A61P1/16

Abstract: Disclosed herein are pharmaceutical compositions to treat, prevent, reduce the incidence of, or reduce the severity of hepatic steatosis comprising an effective amount of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating, preventing, reducing the incidence of, or reducing the severity of hepatic steatosis comprising administering an effective amount of a pharmaceutical composition of one or more mTOR inhibitors and optionally an effective amount of one or more thyroid hormones.

公开(公告)号：US12194198B2

公开(公告)日：2025-01-14

申请号：US16719753

申请日：2019-12-18

Applicant: Access Vascular, Inc.

Inventor： Matthew M. Mannarino ,  Daniel T. Donahue ,  Michael Bassett ,  James F. Biggins

IPC: A61L29/16 ,  A61K9/70 ,  A61K31/155 ,  A61K31/445 ,  A61L29/04 ,  A61L29/06 ,  A61L29/14 ,  A61L31/06 ,  A61L31/14 ,  A61L31/16 ,  A61L29/02 ,  A61L29/18

Abstract: High strength biomedical materials and processes for making the same are disclosed. Included in the disclosure are nanoporous hydrophilic solids that can be extruded with a high aspect ratio to make high strength medical catheters and other devices with lubricious and biocompatible surfaces. Biologically active agents may be entrapped in pores of materials to provide a controlled release of the biologically active agent.

公开(公告)号：US20250000949A1

公开(公告)日：2025-01-02

申请号：US18804421

申请日：2024-08-14

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yang Wei ,  Haruka Okamoto ,  Jesper Gromada ,  Samuel Davis ,  Andrew J. Murphy

IPC: A61K38/26 ,  A61K31/155 ,  A61K31/5415 ,  A61K38/00 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605 ,  C07K16/08 ,  C07K16/28 ,  C12N15/62

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

公开(公告)号：US12171853B2

公开(公告)日：2024-12-24

申请号：US17465546

申请日：2021-09-02

Applicant: Innovative BioDefense, Inc.

Inventor： Jesse Cozean ,  Colette Cozean ,  Susan Goldsberry

IPC: A61K31/045 ,  A61K8/31 ,  A61K8/34 ,  A61K8/41 ,  A61K8/43 ,  A61K8/49 ,  A61K8/67 ,  A61K31/14 ,  A61K31/155 ,  A61K31/355 ,  A61K31/717 ,  A61K31/785 ,  A61K33/30 ,  A61K36/61 ,  A61K45/06 ,  A61Q17/00 ,  A61Q19/00 ,  A61Q19/10

Abstract: Several embodiments disclosed herein relate to formulations having antimicrobial and/or sanitizing effects, and uses of the same. In particular, the formulations and methods of using same provide, in several embodiments, an immediate and a persistent antimicrobial effect against a broad spectrum of microorganisms.

公开(公告)号：US20240398729A1

公开(公告)日：2024-12-05

申请号：US18735829

申请日：2024-06-06

Applicant: Duke University

Inventor： Priya Kishnani ,  Baodong Sun ,  Dwight D. Koeberl

IPC: A61K31/137 ,  A61K31/05 ,  A61K31/12 ,  A61K31/155 ,  A61K31/167 ,  A61K31/192 ,  A61K31/198 ,  A61K31/216 ,  A61K31/277 ,  A61K31/352 ,  A61K31/355 ,  A61K31/385 ,  A61K31/436 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00 ,  A61K38/46 ,  A61K38/47 ,  A61P3/00

Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.

公开(公告)号：US20240374545A1

公开(公告)日：2024-11-14

申请号：US18778440

申请日：2024-07-19

Applicant: THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventor： Kyo Young SONG ,  Mi La CHO ,  Joo Yeon JHUN ,  Yoon Ju JUNG ,  Sojung KIM ,  Seung Yoon LEE ,  Jin Seok WOO ,  Kun Hee LEE

IPC: A61K31/155 ,  A61K35/74 ,  A61P35/00 ,  A61P37/04

Abstract: The method for preventing or treating of cancer includes administering a pharmaceutical composition to a subject in need thereof comprising a compound represented by Chemical Formula 1 below or a pharmaceutically acceptable salt thereof as an active ingredient. wherein the composition inhibits the growth of cancer cells.

公开(公告)号：US20240358649A1

公开(公告)日：2024-10-31

申请号：US18735277

申请日：2024-06-06

Applicant: Pinata Holdings Inc.

Inventor： Michael OGBURN ,  Christopher PRICE

IPC: A61K9/50 ,  A61K9/00 ,  A61K31/155 ,  A61K31/568 ,  A61K38/26 ,  A61K45/06

CPC classification number: A61K9/5042 ,  A61K9/0056 ,  A61K9/0075 ,  A61K9/5089 ,  A61K31/155 ,  A61K31/568 ,  A61K38/26 ,  A61K45/06

Abstract: Provided herein are pharmaceutical compositions, kits comprising pharmaceutical compositions, methods of treating disease, and methods of making compositions and kits described herein. The pharmaceutical compositions described herein are powdery pharmaceutical compositions. The powdery pharmaceutical compositions may be administered by an inhaler device described herein. The powdery pharmaceutical compositions may be administered by gummies described herein.

公开(公告)号：US20240342244A1

公开(公告)日：2024-10-17

申请号：US18292488

申请日：2022-07-27

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Katrin Jennifer Svensson ,  Laetitia Voilquin

IPC: A61K38/19 ,  A61K31/155 ,  A61K45/06 ,  A61P1/16 ,  A61P3/10

CPC classification number: A61K38/19 ,  A61K31/155 ,  A61K45/06 ,  A61P1/16 ,  A61P3/10

Abstract: Compositions and methods are provided for the treatment of one or both of type 2 diabetes and fatty liver disease, e.g. non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The adipokine Isthmin-1 (ISM1) protein increases adipose glucose uptake while suppressing hepatic lipid synthesis.

公开(公告)号：US12109216B2

公开(公告)日：2024-10-08

申请号：US18421914

申请日：2024-01-24

Applicant: Essentialis, Inc.

Inventor： Neil M. Cowen

IPC: A61K31/549 ,  A61K9/00 ,  A61K9/20 ,  A61K9/50 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22

CPC classification number: A61K31/549 ,  A61K9/00 ,  A61K9/0004 ,  A61K9/2054 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K31/137 ,  A61K31/155 ,  A61K31/551 ,  A61K38/27 ,  A61K45/06 ,  C07D285/18 ,  C07D285/22 ,  A61K2300/00 ,  A61K31/549 ,  A61K2300/00 ,  A61K38/27 ,  A61K2300/00 ,  A61K31/155 ,  A61K2300/00 ,  A61K31/551 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00

Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are methods of co-administering KATP channel openers with other drugs (e.g., in combination with growth hormone) to treat diseases of humans and animals (e.g., Prader-Willi Syndrome (PWS), Smith-Magenis syndrome (SMS), and the like.